Corin Group announced today that it received FDA 510(k) clearance for its Apollo robotic-assisted surgical platform.
The Cirencester, UK-based company also picked up clearance for the ApolloKnee software application. Corin Group says it marks “a significant industry milestone” in its commitment to advancing total joint replacement surgery.
Apollo, which features BalanceBot technology, builds upon a decade of Corin Group technology. The company designed it to focus on future enhancements in patient outcomes while providing a more intuitive experience for surgeons.
Corin Group began in robotic-assisted total knee arthroplasty (TKA) with its OMNIBotics technology. Apollo expands its capabilities into additional clinical applications across joint arthroplasty. The company expects Apollo to help it enhance patient satisfaction through objective planning, precise implantation and data-driven learning.
By combining advanced robotic and AI technologies, the company aims for its platform to plan, implement and learn. With clinically proven implants, it intends to deliver improved outcomes and maximize healthcare value.
“The Apollo platform is the result of combining objective planning, precise implementation, and continuous learning in pursuit of the forgotten total joint replacement,” said Dr. Jim Pierrepont, global franchise lead at Corin Group. “The Apollo platform goes beyond personalized alignment of the knee during surgery. Corin’s proprietary BalanceBot technology is the world’s first, and only, system that can achieve personalized dynamic balance for each and every patient, every time.”
